

# Iacopo Peccatori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9402262/publications.pdf>

Version: 2024-02-01

160  
papers

5,222  
citations

117571

34  
h-index

91828

69  
g-index

161  
all docs

161  
docs citations

161  
times ranked

6553  
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial: Strengths and Challenges of Allo-SCT in the Modern Era. <i>Frontiers in Oncology</i> , 2022, 12, 850403.	1.3	1
2	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1389-1398.	1.3	10
3	Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients. <i>Blood</i> , 2021, 137, 1556-1559.	0.6	18
4	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. <i>American Journal of Transplantation</i> , 2021, 21, 1622-1628.	2.6	35
5	Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome. <i>Frontiers in Immunology</i> , 2021, 12, 670822.	2.2	0
6	The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106335.	1.1	9
7	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. <i>Frontiers in Oncology</i> , 2021, 11, 705568.	1.3	4
8	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 731478.	1.3	8
9	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	0.6	26
10	Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type. <i>Current Research in Translational Medicine</i> , 2021, 69, 103313.	1.2	0
11	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA mismatching barrier. <i>Transplant Infectious Disease</i> , 2021, 23, e13551.	0.7	0
12	Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	1
13	Quantitative polymerase chain reaction-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study. <i>Haematologica</i> , 2021, 106, 1480-1483.	1.7	5
14	Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 316-322.	2.0	4
15	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1179-1188.	2.0	49
16	Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. <i>Frontiers in Immunology</i> , 2019, 10, 2319.	2.2	25
17	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019048.	0.5	9
18	Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 1145-1147.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. <i>Nature Communications</i> , 2019, 10, 1065.	5.8	120
20	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	15.2	253
21	Islet Allograft Transplantation in the Bone Marrow of Patients With Type 1 Diabetes: A Pilot Randomized Trial. <i>Transplantation</i> , 2019, 103, 839-851.	0.5	27
22	Lung Ultrasound to Evaluate Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Infection and Chemotherapy</i> , 2019, 51, 386.	1.0	3
23	Nanosphere's Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. <i>Clinical Hematology International</i> , 2019, 1, 120-123.	0.7	2
24	CMV-Specific T Cells Restricted By Shared and Donor, but Not By Host HLA Molecules Reconstitute in the First 180 Days after Allogeneic HSCT and Protect from CMV Reactivation: Results of a Prospective Observational Study. <i>Blood</i> , 2019, 134, 4536-4536.	0.6	0
25	Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1476-1482.	2.0	39
26	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. <i>Bone Marrow Transplantation</i> , 2018, 53, 1201-1205.	1.3	10
27	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. <i>Bone Marrow Transplantation</i> , 2018, 53, 410-416.	1.3	10
28	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1522-1531.	1.3	22
29	Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 213-218.	1.3	8
30	CD3+ Graft Cell Count Predicts Chronic Gvhd Incidence in Haploidentical Allogeneic Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S297.	2.0	0
31	First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature. <i>Frontiers in Immunology</i> , 2018, 9, 113.	2.2	25
32	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	0.6	164
33	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. <i>Blood</i> , 2018, 132, 818-818.	0.6	19
34	Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT. <i>Blood</i> , 2018, 132, 2028-2028.	0.6	1
35	ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3381-3381.	0.6	0
36	Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients. <i>Blood</i> , 2018, 132, 4600-4600.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Immune Reconstitution Is a Predictive Biomarker of Chronic Graft-Versus-Host Disease: Analysis of 307 Consecutive Patients. <i>Blood</i> , 2018, 132, 4579-4579.	0.6	0
38	Combining Whole Exome Sequencing and Rnaseq to Provide a Comprehensive Landscape of the Mechanisms of Post-Transplantation Leukemia Relapse. <i>Blood</i> , 2018, 132, 819-819.	0.6	0
39	Post-Transplant Cyclophosphamide and Sirolimus in Matched Related and Unrelated Allogeneic Transplant with a Treosulfan-Based Conditioning. <i>Blood</i> , 2018, 132, 4662-4662.	0.6	0
40	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. <i>Expert Review of Hematology</i> , 2017, 10, 479-492.	1.0	34
41	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 821-836.	1.4	4
42	Acquired Complement Regulatory Gene Mutations and Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1580-1582.	2.0	17
43	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017, 92, 1011-1019.	2.0	14
44	Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2017, 123, 2671-2679.	2.0	37
45	A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2151-2158.	2.0	9
46	Control of infectious mortality due to carbapenemase-producing <i>Klebsiella pneumoniae</i> in hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 114-119.	1.3	33
47	Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx215.	0.4	45
48	Elderly patients >65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. <i>American Journal of Hematology</i> , 2016, 91, E302-3.	2.0	2
49	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, e157-e161.	1.7	55
50	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1022-1024.	1.3	6
51	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2250-2255.	2.0	36
52	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. <i>Blood</i> , 2016, 128, 1528-1531.	0.6	46
53	Autologous Islet Transplantation in Patients Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis. <i>American Journal of Transplantation</i> , 2016, 16, 1812-1826.	2.6	46
54	Secondary SOLID Tumors after Allogeneic STEM CELL Transplantation: A CROSS-Sectional Evaluation in 260 Adults at 1-Year Follow-up. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S189-S190.	2.0	0

#	ARTICLE	IF	CITATIONS
55	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. <i>Hematological Oncology</i> , 2016, 34, 154-160.	0.8	6
56	Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. <i>Bone Marrow Transplantation</i> , 2016, 51, 466-469.	1.3	6
57	High rate of hematological responses to sorafenib in <scp>FLT</scp>3<sc>ITD</sc> acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 629-636.	1.1	35
58	Escalated Dose-Rates of Total Marrow Irradiation (TMI) Combined with Treosulfan and Fludarabine-Based Conditioning Chemotherapy Regimen for Chemosensitive Advanced Multiple Myeloma (MM) Patients Undergoing a Matched Allogeneic Stem-Cell Transplantation: First Results of a Phase I/II Prospective Monocentric Study (TrRaMM TMI). <i>Blood</i> , 2016, 128, 2221-2221.	0.6	1
59	Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients. <i>Blood</i> , 2016, 128, 3442-3442.	0.6	1
60	Multiple Inhibitory Receptors Are Expressed on Central Memory and Memory Stem T Cells Infiltrating the Bone Marrow of AML Patients Relapsing after Allo-HSCT. <i>Blood</i> , 2016, 128, 4564-4564.	0.6	3
61	Post-Transplant Treatment with Ponatinib for Patients with High-Risk Philadelphia Chromosome Positive Leukemia. <i>Blood</i> , 2016, 128, 5810-5810.	0.6	1
62	Longitudinal Microbiome Profile in Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Study in 100 Patients. <i>Blood</i> , 2016, 128, 3435-3435.	0.6	0
63	Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3492-3492.	0.6	0
64	How to Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation: A Survey from the EBMT- Cellular Therapy & Immunobiology Working Party. <i>Blood</i> , 2016, 128, 4581-4581.	0.6	0
65	Pre-Transplant Colonization By a Multidrug-Resistant Gram Negative Bacteria Has No Impact on Overall Survival and Mortality after Hematopoietic Stem Cell Transplantation: A Single-Center Experience in 362 Patients. <i>Blood</i> , 2016, 128, 5743-5743.	0.6	0
66	Pentraxin 3 As a Novel Diagnostic and Prognostic Biomarker for Acute GvHD and Fungal Infections in Adult Allogeneic HSCT Recipients. <i>Blood</i> , 2016, 128, 4600-4600.	0.6	1
67	Role of Cell Source and Graft Composition in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 4664-4664.	0.6	0
68	Biomarkers Predicting Acute GvHD and Transplant Outcomes in 120 Consecutive Allogeneic HSCT Recipients. <i>Blood</i> , 2016, 128, 2240-2240.	0.6	0
69	HHV6 Specific T-Cells Are Predictive Biomarker of Active HHV6 Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Study in 213 Patients. <i>Blood</i> , 2016, 128, 3399-3399.	0.6	0
70	Infection-Related Mortality (IRM) after Allogeneic Hematopoietic Stem Cell Transplantation: Age, CMV Status, Pre-Transplant IgA and IgM Levels Predict IRM and Survival in a New Clinico-Biological Scoring System Developed in 492 Consecutive Patients. <i>Blood</i> , 2016, 128, 2220-2220.	0.6	1
71	Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy. <i>Blood</i> , 2016, 128, 4567-4567.	0.6	0
72	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. <i>Blood</i> , 2015, 125, 2865-2874.	0.6	119

#	ARTICLE	IF	CITATIONS
73	Improving the safety of cell therapy with the TK-suicide gene. <i>Frontiers in Pharmacology</i> , 2015, 6, 95.	1.6	102
74	Haploidentical HSCT: a 15-year experience at San Raffaele. <i>Bone Marrow Transplantation</i> , 2015, 50, S67-S71.	1.3	6
75	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1506-1514.	2.0	121
76	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. <i>Science Translational Medicine</i> , 2015, 7, 317ra198.	5.8	102
77	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. <i>Leukemia</i> , 2015, 29, 396-405.	3.3	114
78	Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. <i>Leukemia</i> , 2015, 29, 1143-1152.	3.3	110
79	Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. <i>Bone Marrow Transplantation</i> , 2015, 50, 1262-1264.	1.3	11
80	Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients. <i>Blood</i> , 2015, 126, 4400-4400.	0.6	1
81	HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics. <i>Blood</i> , 2015, 126, 743-743.	0.6	2
82	Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 4335-4335.	0.6	0
83	Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults. <i>Blood</i> , 2015, 126, 4362-4362.	0.6	0
84	Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants. <i>Blood</i> , 2015, 126, 5465-5465.	0.6	0
85	Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory. <i>Blood</i> , 2015, 126, 263-263.	0.6	0
86	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. <i>Frontiers in Immunology</i> , 2014, 5, 16.	2.2	126
87	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453.	2.8	43
88	Wilms' Tumor Gene 1 Transcript Levels in Leukapheresis of Peripheral Blood Hematopoietic Cells Predict Relapse Risk in Patients Autografted for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1586-1591.	2.0	26
89	Bortezomib and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. <i>American Journal of Hematology</i> , 2014, 89, 1085-1091.	2.0	45
90	Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1444-1447.	2.0	21

#	ARTICLE	IF	CITATIONS
91	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. Diabetes 2013;62:3523-3531. Diabetes, 2014, 63, 377-377.	0.3	0
92	Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study. Blood, 2014, 124, 196-196.	0.6	11
93	Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in High Risk Haematological Diseases: A 10-Years Evaluation at San Raffaele Scientific Institute. Blood, 2014, 124, 2498-2498.	0.6	6
94	Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study. Blood, 2014, 124, 2535-2535.	0.6	5
95	Sirolimus and Post Transplant Cyclophosphamide (PT-Cy) Allow the Use of Haploidentical PBSC Grafts Inducing a Favorable Immune Reconstitution with Low Rates of GvHD: Results in 39 Patients. Blood, 2014, 124, 2584-2584.	0.6	1
96	Droplet Digital PCR for DNMT3A and IDH1/2 Mutations to Improve Early Diagnosis of Acute Myeloid Leukemia Relapse after Allogeneic HSCT. Blood, 2014, 124, 3951-3951.	0.6	1
97	Acute Myeloid Leukemia Relapses after Allogeneic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation. Blood, 2014, 124, 427-427.	0.6	9
98	Revealing the Generation of Human Memory Stem T Cells in Haploidentical T-Replete Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 192-192.	0.6	0
99	Rapid Molecular Detection of Pathogens in 516 Consecutive Haematological Patients with Febrile Neutropenia. Blood, 2014, 124, 2750-2750.	0.6	0
100	Early Blast Clearance Evaluation after Induction Chemotherapy for Acute Myeloid Leukemia By Multiparameter Flow Cytometry and WT1-RNA Quantification: A Single Center Experience. Blood, 2014, 124, 5333-5333.	0.6	0
101	Haploidentical Hematopoietic Stem Cell Transplantation with Treosulfan-Based Conditioning Regimen for Acute Leukemia Relapsing after Initial Allogeneic Transplantation. Blood, 2014, 124, 3956-3956.	0.6	4
102	Human Herpes Virus 6 Infection in 54 Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Manifestations and Outcome. Blood, 2014, 124, 3899-3899.	0.6	0
103	Haploidentical Allogeneic Stem Cell Transplantation in Poor Risk Cytogenetic Acute Myeloid Leukemia: Results in 33 Patients. Blood, 2014, 124, 5942-5942.	0.6	0
104	Autologous Pancreatic Islet Transplantation in Human Bone Marrow. Diabetes, 2013, 62, 3523-3531.	0.3	90
105	IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood, 2013, 121, 573-584.	0.6	455
106	Post-Transplant Cyclophosphamide Haplo-HSCT Revised: Peripheral Blood Stem Cell Graft and Sirolimus To Enhance Immune Reconstitution and Graft Versus Leukemia Effect In Patients With Active Leukemia. Blood, 2013, 122, 2118-2118.	0.6	2
107	Allogeneic Hematopoietic Stem Cell Transplantation For Severe Neuromyelitis Optica. Blood, 2013, 122, 5539-5539.	0.6	1
108	Incidence, Risk Factors and Clinical Outcome Of Leukemia Relapses Due To Loss Of The Mismatched HLA Haplotype After Partially-Incompatible Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 918-918.	0.6	1

#	ARTICLE	IF	CITATIONS
109	High-Sensitivity Hematopoietic Chimerism By qPCR For Relapse Prediction and Specific Identification Of HLA Loss Leukemic Variants. <i>Blood</i> , 2013, 122, 3313-3313.	0.6	0
110	Modeling Antileukemic Adoptive Immunotherapy In Mouse-Humans Chimeras To Identify Novel Mechanisms Of Cancer Immunoediting. <i>Blood</i> , 2013, 122, 2017-2017.	0.6	1
111	Non-Linear Clonal Evolution Of Leukemia Driven By Selective Immune Pressure and Revealed By HLA Typing and High-Depth Exome Sequencing. <i>Blood</i> , 2013, 122, 1369-1369.	0.6	0
112	Treosulfan Based Myeloablative Regimen Provides High Rate Of Allogeneic Engraftment and Low Toxicity In Patients With Advanced Myelofibrosis,. <i>Blood</i> , 2013, 122, 5504-5504.	0.6	1
113	Intensification Of Treosulfan and Fludarabine-Based Conditioning With 4 Gy TBI For Allogeneic Stem Cell Transplantation In Patients With Hematological Malignancies. <i>Blood</i> , 2013, 122, 2149-2149.	0.6	0
114	Primary Bone Marrow Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 296-304.	2.1	59
115	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 120, 1820-1830.	0.6	47
116	Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. <i>Blood</i> , 2012, 119, 4813-4815.	0.6	42
117	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	0.6	260
118	Haploidentical Transplantation Outcome Is Not Inferior to Standard Matched Related and Unrelated Donor Transplantation: An Intention-to-Treat Analysis of 241 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1920-1920.	0.6	1
119	Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates. <i>Blood</i> , 2012, 120, 4191-4191.	0.6	28
120	Full Dose Treosulfan Based Reduced Toxicity Conditioning Regimen in Allogeneic Stem Cell Transplantation: Results in 123 Patients.. <i>Blood</i> , 2012, 120, 3139-3139.	0.6	0
121	Loss of Mismatched HLA At Leukemia Relapse After Hematopoietic Stem Cell Transplantation Is Significantly Associated with Clinical and Immunogenetic Hallmarks of Donor-Versus-Host Alloreactivity. <i>Blood</i> , 2012, 120, 1957-1957.	0.6	3
122	Improved Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Metastatic Renal Cancer Associated with Homozygosity for the HLA-G 14 Base-Pair Deletion Polymorphism: An EBMT STWP Study. <i>Blood</i> , 2012, 120, 4667-4667.	0.6	1
123	Evaluating CD8+ Memory Stem T Cells Dynamics After Allogeneic Bone Marrow Transplantation: Impact On GvHD Occurrence. <i>Blood</i> , 2012, 120, 4179-4179.	0.6	0
124	Evaluation of NIH-Defined Chronic Graft-Versus-Host-Disease in a Rapamycin-Based Haploidentical Stem Cell Transplantation: Analysis of 113 Consecutive Patients with High Risk Haematological Malignancies. <i>Blood</i> , 2012, 120, 4198-4198.	0.6	0
125	Unmanipulated Graft Transplantation From Family Haploidentical Donors: A Survey On 183 Adult Patients with Acute Leukemias On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2012, 120, 1987-1987.	0.6	0
126	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	3.3	51



#	ARTICLE	IF	CITATIONS
127	Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). <i>Journal of Cancer</i> , 2011, 2, 347-349.	1.2	2
128	Combining allografting with mTOR inhibitors for metastatic renal cell cancer. <i>Bone Marrow Transplantation</i> , 2011, 46, 1586-1586.	1.3	1
129	Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. <i>Journal of Cancer</i> , 2011, 2, 339-340.	1.2	12
130	Allogeneic hematopoietic stem cell transplantation in ovarian cancer—the EBMT experience. <i>International Journal of Cancer</i> , 2010, 127, 1446-1452.	2.3	9
131	Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. <i>Bone Marrow Transplantation</i> , 2010, 45, 385-391.	1.3	53
132	Allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 857-859.	1.7	26
133	Implementation of An Alternative Donor Option Is Prerequisite for a Good Intention-to-Treat (ITT) In Patients In Need of Allogeneic Transplantation: Analysis of 410 Patients. <i>Blood</i> , 2010, 116, 2382-2382.	0.6	0
134	Thymic Renewal and Anti-Leukemic Effect In Adults After Haploidentical Transplantation and Donor T Cell Suicide Gene Therapy. <i>Blood</i> , 2010, 116, 833-833.	0.6	0
135	Effect of Related and Unrelated Donor Haemopoietic Stem-Cell Transplantation on Outcome In Adults with High Risk Acute Leukemia: An Intention-to-Treat Analysis at a Single Center Institution. <i>Blood</i> , 2010, 116, 2385-2385.	0.6	17
136	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. <i>Bone Marrow Transplantation</i> , 2009, 44, 237-242.	1.3	18
137	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2009, 361, 478-488.	13.9	459
138	43-OR: Genomic loss of mismatched HLA in leukemia is a major mechanism of in vivo escape from T cell immunosurveillance following haploidentical hematopoietic stem cell transplantation. <i>Human Immunology</i> , 2009, 70, S167.	1.2	0
139	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. <i>Lancet Oncology</i> , 2009, 10, 489-500.	5.1	458
140	Interleukin-10 Energized Donor T Cell Infusion Improves Immune Reconstitution without Severe Graft-Versus-Host-Disease After Haploidentical Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 45-45.	0.6	12
141	Rapamycin-Based GvHD Prophylaxis Is Effective in T-Cell Replete Unmanipulated Haploidentical Peripheral Stem Cell Transplantation for Advanced Haematological Malignancies: Results in 46 Patients.. <i>Blood</i> , 2009, 114, 666-666.	0.6	0
142	Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. <i>Leukemia</i> , 2008, 22, 2119-2122.	3.3	12
143	Pre-transplant 18F-FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 727-733.	0.6	27
144	Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3488-3499.	0.6	113

#	ARTICLE	IF	CITATIONS
145	Genomic Loss of the Mismatched HLA Locus in Leukemia Is a Major Mechanism of in Vivo Escape from T Cell Immunosurveillance Following Haploidentical HSCT. <i>Blood</i> , 2008, 112, 828-828.	0.6	4
146	Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality. <i>Blood</i> , 2008, 112, 353-353.	0.6	0
147	Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. <i>Blood</i> , 2007, 109, 4698-4707.	0.6	171
148	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 497-499.	2.0	5
149	Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. <i>Journal of Translational Medicine</i> , 2007, 5, 35.	1.8	7
150	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. <i>Histopathology</i> , 2006, 48, 529-535.	1.6	14
151	Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. <i>Bone Marrow Transplantation</i> , 2006, 37, 311-315.	1.3	2
152	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. <i>Annals of Oncology</i> , 2006, 17, 1134-1140.	0.6	84
153	Rapid and Wide Immunoreconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT.. <i>Blood</i> , 2006, 108, 307-307.	0.6	4
154	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2006, 91, 837-9.	1.7	38
155	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. <i>Cancer</i> , 2005, 104, 2099-2103.	2.0	50
156	Incidence of Human Cytomegalovirus Infection in Patients with Refractory Solid Tumors Receiving Nonmyeloablative Allogeneic Stem Cell Transplants versus Recipients of Standard SCT for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 423-428.	2.0	5
157	Allogeneic stem cell transplantation for the treatment of advanced solid tumors. <i>Seminars in Immunopathology</i> , 2004, 26, 95-108.	4.0	18
158	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. <i>Blood</i> , 2002, 99, 4234-4236.	0.6	209
159	Allogeneic Non-Myeloablative Peripheral-Blood Stem Cell Transplant in Solid Tumors. <i>Tumori</i> , 2002, 1, S32-S33.	0.6	3
160	Pulmonary lymphangiioleimoyomatosis and renal papillary cancer: incomplete expression of tuberous sclerosis?. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 2740-2743.	0.4	6